Invesco Ltd. Sells 104,445 Shares of BioCryst Pharmaceuticals, Inc. $BCRX

Invesco Ltd. lessened its stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 9.7% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 968,155 shares of the biotechnology company’s stock after selling 104,445 shares during the quarter. Invesco Ltd. owned approximately 0.46% of BioCryst Pharmaceuticals worth $7,261,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of the stock. Allianz Asset Management GmbH boosted its position in BioCryst Pharmaceuticals by 9.6% during the 1st quarter. Allianz Asset Management GmbH now owns 13,700 shares of the biotechnology company’s stock valued at $103,000 after acquiring an additional 1,200 shares in the last quarter. SG Americas Securities LLC boosted its position in BioCryst Pharmaceuticals by 5.2% during the 1st quarter. SG Americas Securities LLC now owns 43,496 shares of the biotechnology company’s stock valued at $326,000 after acquiring an additional 2,146 shares in the last quarter. Mariner LLC boosted its position in BioCryst Pharmaceuticals by 32.1% during the 4th quarter. Mariner LLC now owns 13,258 shares of the biotechnology company’s stock valued at $100,000 after acquiring an additional 3,224 shares in the last quarter. Quantinno Capital Management LP boosted its position in BioCryst Pharmaceuticals by 38.2% during the 4th quarter. Quantinno Capital Management LP now owns 14,828 shares of the biotechnology company’s stock valued at $112,000 after acquiring an additional 4,097 shares in the last quarter. Finally, Headlands Technologies LLC bought a new stake in BioCryst Pharmaceuticals during the 1st quarter valued at $32,000. Institutional investors own 85.88% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have issued reports on BCRX shares. JPMorgan Chase & Co. increased their target price on BioCryst Pharmaceuticals from $10.00 to $13.00 and gave the company an “overweight” rating in a research report on Tuesday, May 6th. Needham & Company LLC reiterated a “buy” rating and set a $17.00 price objective on shares of BioCryst Pharmaceuticals in a report on Monday, August 4th. Wedbush increased their price objective on BioCryst Pharmaceuticals from $16.00 to $18.00 and gave the company an “outperform” rating in a report on Monday, June 30th. HC Wainwright reiterated a “buy” rating and set a $30.00 price objective on shares of BioCryst Pharmaceuticals in a report on Tuesday, May 6th. Finally, Bank of America increased their price objective on BioCryst Pharmaceuticals from $13.00 to $15.00 and gave the company a “buy” rating in a report on Tuesday, July 1st. Nine equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat.com, BioCryst Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $16.70.

Insider Buying and Selling at BioCryst Pharmaceuticals

In other BioCryst Pharmaceuticals news, Director Theresa Heggie sold 70,000 shares of BioCryst Pharmaceuticals stock in a transaction dated Wednesday, August 13th. The stock was sold at an average price of $8.51, for a total transaction of $595,700.00. Following the completion of the transaction, the director owned 65,352 shares in the company, valued at approximately $556,145.52. This trade represents a 51.72% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 5.10% of the company’s stock.

BioCryst Pharmaceuticals Price Performance

Shares of BCRX stock opened at $8.58 on Wednesday. The firm has a market capitalization of $1.80 billion, a price-to-earnings ratio of -47.66, a price-to-earnings-growth ratio of 1.91 and a beta of 1.10. The business has a fifty day moving average of $8.76 and a 200 day moving average of $8.79. BioCryst Pharmaceuticals, Inc. has a 1 year low of $6.01 and a 1 year high of $11.31.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its quarterly earnings data on Monday, August 4th. The biotechnology company reported $0.15 earnings per share for the quarter, beating analysts’ consensus estimates of $0.03 by $0.12. The company had revenue of $163.35 million for the quarter, compared to analysts’ expectations of $149.59 million. The business’s quarterly revenue was up 49.5% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.06) EPS. As a group, equities research analysts expect that BioCryst Pharmaceuticals, Inc. will post -0.36 earnings per share for the current year.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.